SARS-CoV-2 Immunogenicity in individuals infected before and after COVID-19 vaccination: Israel, January-March 2021: Implications for vaccination policy

Article activity feed

1. 

   ScreenIT

   Apr 18, 2021

   SciScore for 10.1101/2021.04.11.21255273: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IRB: The study was approved by Ziv Medical Center’s ethics committee (approval number: 0133–20-ZIV).
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   , Nucleocapsid (N) IgG antibody levels were measured in consenting workers, using a highly sensitive and specific SARS-CoV-2 IgG qualitative assay (Abbott, Abbot Park, US) (10), followed by a quantitative LIAISON SARS-CoV-2 S1/S2 IgG PCR test (DiaSorin, Saluggia, Italy) for verification purposes (10).	Nucleocapsid ( N ) IgG suggested: None
   All the individuals with detectable IgG antibodies at baseline …

   SciScore for 10.1101/2021.04.11.21255273: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IRB: The study was approved by Ziv Medical Center’s ethics committee (approval number: 0133–20-ZIV).
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   , Nucleocapsid (N) IgG antibody levels were measured in consenting workers, using a highly sensitive and specific SARS-CoV-2 IgG qualitative assay (Abbott, Abbot Park, US) (10), followed by a quantitative LIAISON SARS-CoV-2 S1/S2 IgG PCR test (DiaSorin, Saluggia, Italy) for verification purposes (10).	Nucleocapsid ( N ) IgG suggested: None
   All the individuals with detectable IgG antibodies at baseline and/or evidence of a previous positive PCR test SARS-CoV-2 were considered previously infected.	detectable IgG suggested: None
   Anti-SARS-CoV2 spike IgG antibody levels were compared among groups of ZMC workers according to the number of doses received (1 or 2) and their infection status (uninfected, infected prior to vaccination, infected after vaccination).	Anti-SARS-CoV2 spike IgG suggested: None
   Software and Algorithms
   Sentences	Resources
   , Nucleocapsid (N) IgG antibody levels were measured in consenting workers, using a highly sensitive and specific SARS-CoV-2 IgG qualitative assay (Abbott, Abbot Park, US) (10), followed by a quantitative LIAISON SARS-CoV-2 S1/S2 IgG PCR test (DiaSorin, Saluggia, Italy) for verification purposes (10).	Abbott suggested: (Abbott, RRID:SCR_010477)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
2. 

   Version published to 10.1101/2021.04.11.21255273 on medRxiv

   Apr 16, 2021
3. Version published to 10.1017/s0950268821001928

   Jan 1, 2021